Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. (Q36980135)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 April 2013

Language	Label	Description	Also known as
English	Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.	scientific article published on 12 April 2013

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Dana M Roque

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Stefania Bellone

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Diana P English

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Natalia Buza

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Emiliano Cocco

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Sara Gasparrini

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Ileana Bortolomai

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Elena Ratner

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Dan-Arin Silasi

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Thomas J Rutherford

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Peter E Schwartz

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Alessandro D Santin

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

0 references

publication date

12 April 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

119

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2582-2592

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Treatment options for advanced endometrial carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Intercepting pelvic cancer in the distal fallopian tube: theories and realities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Beyond chemotherapy: targeted therapies in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Molecular mechanisms of patupilone resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Overexpression of mammaglobin B in epithelial ovarian carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Integrated genomic and proteomic analyses of gene expression in Mammalian cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

The Role of ABC Transporters in Clinical Practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Endometrial papillary serous carcinoma: patterns of spread and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Two pathogenetic types of endometrial carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

29 September 2017

Expression of ERCC1, p53, and class III β-tubulin do not reveal chemoresistance in endometrial cancer: results from an immunohistochemical study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

4 September 2018

Expression of tubulin, p53, ki67, receptors for estrogen, and progesterone in endometrial cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

4 September 2018

The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

4 September 2018

Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

4 September 2018

High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700638

4 September 2018

Uterine papillary serous carcinomas: the exigency for clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/23585021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Grading ovarian serous carcinoma using a two-tier system

1 reference

https://pubmed.ncbi.nlm.nih.gov/23585021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Uterine papillary serous carcinoma: patterns of metastatic spread

1 reference

https://pubmed.ncbi.nlm.nih.gov/23585021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reverse correlation between P-glycoprotein expression and proliferative activity in endometrial adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23585021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry

1 reference

https://pubmed.ncbi.nlm.nih.gov/23585021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23585021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23585021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.28017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585021%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36980135&oldid=1514457578"